MHRA Resassures Thalidomide Preganancy Prevention Programme Will Continue

21st May 2020

MHRA provide reassurance of continuation of thalidomide pregnancy prevention programme during Covid-19 Pandemic

New guidance has been issued today by the Medicines and Healthcare products Regulatory Agency (MHRA). These provide reassurance that, despite temporary changes to prescribing practice for patients who are shielding, stringent controls will remain in place to prevent infants being exposed to thalidomide during pregnancy .